Evaluation and management of platelet transfusion refractoriness
- Author:
Hee-Jeong YOUK
1
;
Sang-Hyun HWANG
;
Heung-Bum OH
;
Dae-Hyun KO
Author Information
- Publication Type:REVIEW ARTICLE
- From:Blood Research 2022;57(S1):S6-S10
- CountryRepublic of Korea
- Language:English
- Abstract: Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common is human leukocyte antigen (HLA) class I molecules. PTR caused by anti-HLA antibodies is usually managed by transfusing HLA-matched platelets. Therefore, it is important, especially for hemato-oncologists who frequently perform transfusion, to accurately diagnose whether the cause of platelet transfusion failure is alloimmune or non-immunological when determining the treatment direction for the patient. In this review, we discuss the definitions, causes, countermeasures, and prevention methods of PTR.
